Comparative Pharmacology
Head-to-head clinical analysis: RYBREVANT versus RYBREVANT FASPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RYBREVANT versus RYBREVANT FASPRO.
RYBREVANT vs RYBREVANT FASPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RYBREVANT (amivantamab-vmjw) is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) receptor, blocking ligand binding and inducing receptor degradation. It also mediates antibody-dependent cellular cytotoxicity (ADCC) against tumor cells overexpressing EGFR and MET.
RYBREVANT FASPRO (amivantamab-vmjw) is a bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding and receptor activation, leading to downregulation of downstream signaling pathways (e.g., MAPK, PI3K/AKT) involved in cell proliferation and survival, and induces antibody-dependent cellular cytotoxicity (ADCC).
RYBREVANT (amivantamab-vmjw) is administered intravenously. The recommended dose is 1050 mg (weight <80 kg) or 1400 mg (weight ≥80 kg) once weekly for 4 weeks, then every 2 weeks thereafter. Administer as a 60-minute infusion for the first dose, 40-minute infusion for the second dose, and 30-minute infusion for subsequent doses.
RYBREVANT (amivantamab-vmjw) is administered intravenously. The recommended dose is 1050 mg (for patients <80 kg) or 1400 mg (for patients ≥80 kg) once weekly for the first 4 weeks (Cycle 1, Days 1, 8, 15, 22), then every 2 weeks (Cycle 2 and subsequent, Days 1 and 15) starting on Day 29. Each dose is given as an IV infusion over 60 minutes (first infusion) or over 40 minutes (subsequent infusions if tolerated).
None Documented
None Documented
Terminal half-life is approximately 11.3 days (range 4.2–30.4 days) at the recommended dose. This supports a dosing interval of every 2 weeks after initial weekly loading doses.
Terminal elimination half-life approximately 11 days (range 7-17 days) supporting every-2-week dosing regimen.
RYBREVANT (amivantamab) is a monoclonal antibody that undergoes catabolism to small peptides and amino acids. No specific excretion studies have been conducted; endogenous IgG is eliminated primarily via intracellular catabolism. Fecal excretion is minimal (<1%).
Primarily catabolized via proteolysis; renal excretion of intact drug is minimal. Biliary/fecal excretion not characterized.
Category C
Category C
Bispecific EGFR-MET Antibody Antineoplastic
Bispecific EGFR-MET Antibody Antineoplastic